As many as 70 medicines may get cheaper at the National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of a total of 70 new drug formulations. Reportedly, this also involves 12 drugs for which the companies launched the products without obtaining price approval from the Authority.
According to a report by Pharmabiz, the 58 formulations for which the retail prices were fixed in a recent meeting held by the Authority include paracetamol infusion Ip from Dr Reddy’s Laboratories, combination of metoprolol succinate (extended release), amlodipine and telmisartan tablet from Ipca Laboratories, paracetamol tablet IP 1000 mg from Alkem Laboratories, combination of metoprolol succinate (extended release), amlodipine and telmisartan tablet from Mankind Pharma, Combikit of clarithromycin tablets, esomeprazole tablets and amoxicillin tablets from Natco Pharma, rosuvastatin and clopidogrel combination from Torrent Pharmaceuticals, and combination of fexofenadine hydrochloride and montelukast tablets from Sun Pharmaceuticals Industries Ltd, among others.
During the meeting, retail price of the combination ceftazidime and avibactam powder for concentrate solution for infusion from Zyphars Pharmaceuticals has been fixed at Rs. 1,572.59 per vial.
“The Authority deliberated upon the worked-out price, claimed price and launched price and approved the lowest of the three prices as the retail price of the new drugs….,” NPPA stated.
These include the combination of telmisartan and chlorthalidone tablets, combinations of sitagliptin and metformin hydrochloride from Corona Remedies, a combination of dapagliflozin, vildagliptin sustained release (SR) and metformin hydrochloride (SR) and combinations of dapagliflozin, sitagliptin and metformin hydrochloride (extended release) from Macleods Pharmaceuticals, dapagliflozin, sitagliptin and metformin hydrochloride (extended release) tablets from Unison Pharmaceuticals, combination of teneligliptin, dapagliflozin and metformin hydrochloride (SR) tablets in two different strengths from Glenmark Pharmaceuticals, among others.
The NPPA fixes the retail prices of new drug formulations based on applications from individual companies, under Para 5 and 15 of the Drugs Prices Control Order (DPCO), 2013 from time to time.
